The James Buchannan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Department of Plastic and Reconstructive Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.
J Urol. 2017 Aug;198(2):274-280. doi: 10.1016/j.juro.2016.10.134. Epub 2017 Mar 10.
Reconstruction of complex functional structures is increasingly being performed with vascularized composite allotransplantation. Penile transplantation is a novel vascularized composite allotransplantation treatment option for severe penile tissue loss and disfigurement. Three allogeneic human penile transplantations have been reported. We review these cases as well as penile transplant indications, preclinical models and immunosuppression therapy.
We performed a comprehensive literature review for the years 1970 to 2016 via MEDLINE®, PubMed® and Google with the key words "penis transplantation," "penile rejection," "penile replantation," "penile tissue loss" and "penis vascularized composite allotransplantation." Relevant articles, including original research, reviews and nonscientific press reports, were selected based on contents, and a review of this literature was generated.
Three human allogeneic penile transplantations have been performed to date, of which 1 was removed 14 days after transplantation. The second recipient reports natural spontaneous erections and impregnating his partner. All 3 patients were able to void spontaneously through the graft's urethra. The complexity of the transplant is determined by how proximally the penile shaft anastomosis is performed and additional pelvic tissue may be transplanted en bloc if needed.
Penile transplantation is a technically demanding procedure with significant ethical and psychosocial implications that can provide tissue and functional replacement, including urinary diversion and natural erections. It is unclear how rejection and immunosuppression may affect graft function. Better models and more preclinical research are needed to better understand and optimize penile transplantation.
带血管复合组织同种异体移植术越来越多地用于重建复杂的功能结构。阴茎移植是治疗严重阴茎组织缺失和畸形的新型带血管复合组织同种异体移植治疗方法。已经报道了三例同种异体人类阴茎移植。我们回顾了这些病例以及阴茎移植的适应证、临床前模型和免疫抑制治疗。
我们通过 MEDLINE ® 、 PubMed ® 和 Google 对 1970 年至 2016 年的文献进行了全面的文献回顾,关键词为“阴茎移植”、“阴茎排斥”、“阴茎再植”、“阴茎组织缺失”和“阴茎带血管复合组织同种异体移植”。选择了基于内容的相关文章,包括原始研究、综述和非科学新闻报道,并生成了对该文献的综述。
迄今为止,已经进行了三例人类同种异体阴茎移植,其中 1 例在移植后 14 天被移除。第二位受者报告自然自发勃起并使他的伴侣怀孕。所有 3 例患者均能通过移植物的尿道自行排尿。移植的复杂性取决于阴茎干吻合的近端位置,如果需要,还可以整块移植其他骨盆组织。
阴茎移植是一种技术要求很高的手术,具有重大的伦理和心理社会影响,可以提供组织和功能替代,包括尿流改道和自然勃起。排斥和免疫抑制如何影响移植物功能尚不清楚。需要更好的模型和更多的临床前研究来更好地理解和优化阴茎移植。